PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend
WALTHAM, Mass.–(BUSINESS WIRE)–Sep. 17, 2021– PerkinElmer, Inc. (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion. The acquisition, the largest in PerkinElmer’s history, further expands the... Read more